Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3076799 | 1.00 | BCHE (0.32) | BCHEHTR7DRD2SLC6A4 | |
| SCHEMBL3069603 | 0.99 | HTR7 (0.31) | BCHEHTR7DRD2SLC6A4 | |
| SCHEMBL3075018 | 0.89 | ACP3 (0.31) | BCHE | |
| SCHEMBL3066534 | 0.89 | ACP3 (0.31) | BCHE | |
| SCHEMBL3067745 | 0.89 | — | — | |
| SCHEMBL3061335 | 0.89 | — | — | |
| SCHEMBL3061293 | 0.88 | — | — | |
| SCHEMBL3075282 | 0.88 | — | — | |
| SCHEMBL3074861 | 0.86 | BCHE (0.31) | BCHE | |
| SCHEMBL3061349 | 0.86 | BCHE (0.31) | BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299287-B2 | Metallocene compounds, catalysts comprising them, process for producing an olefin polymer by use of the catalysts, and olefin homo- and copolymers | Lammus Novolen Technology GmbH (DE) | 2012-10-30 | — | — | US | claimed |
| US-20100267907-A1 | METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO-AND COPOLYMERS | LUMMUS NOVOLEN TECHNOLOGY GMBH (DE) | 2010-10-21 | — | — | US | claimed |
| US-8507706-B2 | Metallocene compounds, catalysts comprising them, process for producing an olefin polymer by use of the catalysts, and olefin homo- and copolymers | LUMMUS NOVOLEN TECHNOLOGY GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| US-20120329964-A1 | METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO- AND COPOLYMERS | LUMMUS NOVOLEN TECHNOLOGY GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-8299287-B2 | Metallocene compounds, catalysts comprising them, process for producing an olefin polymer by use of the catalysts, and olefin homo- and copolymers | Lammus Novolen Technology GmbH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-20100267907-A1 | METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO-AND COPOLYMERS | LUMMUS NOVOLEN TECHNOLOGY GMBH (DE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329964-A1 | METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO- AND COPOLYMERS | PIN1, PCNA, OPRM1 | BCHE 1885/4885HTR7 455/4885DRD2 1391/4885 |
| US-20100267907-A1 | METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO-AND COPOLYMERS | PIN1, PCNA, OPRM1 | BCHE 1885/4885HTR7 455/4885DRD2 1391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.